582 related articles for article (PubMed ID: 10769633)
21. Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Kim WS; Park C; Jung YS; Kim HS; Han J; Park CH; Kim K; Kim J; Shim YM; Park K
Anticancer Res; 1999; 19(1A):301-6. PubMed ID: 10226558
[TBL] [Abstract][Full Text] [Related]
22. Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Periyasamy S; Ammanamanchi S; Tillekeratne MP; Brattain MG
Oncogene; 2000 Sep; 19(40):4660-7. PubMed ID: 11030155
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
Miyafuji Y; Zhong X; Uchida I; Koi M; Hemmi H
J Cell Physiol; 2001 Jun; 187(3):356-64. PubMed ID: 11319759
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor-beta receptor expression in human cornea.
Joyce NC; Zieske JD
Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):1922-8. PubMed ID: 9331255
[TBL] [Abstract][Full Text] [Related]
26. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
[TBL] [Abstract][Full Text] [Related]
27. Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells.
Ijichi H; Ikenoue T; Kato N; Mitsuno Y; Togo G; Kato J; Kanai F; Shiratori Y; Omata M
Biochem Biophys Res Commun; 2001 Nov; 289(2):350-7. PubMed ID: 11716479
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.
Fink SP; Mikkola D; Willson JK; Markowitz S
Oncogene; 2003 Mar; 22(9):1317-23. PubMed ID: 12618756
[TBL] [Abstract][Full Text] [Related]
29. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.
Woodford-Richens KL; Rowan AJ; Gorman P; Halford S; Bicknell DC; Wasan HS; Roylance RR; Bodmer WF; Tomlinson IP
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9719-23. PubMed ID: 11481457
[TBL] [Abstract][Full Text] [Related]
30. Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.
Park SH; Kim YS; Park BK; Hougaard S; Kim SJ
Oncogene; 2001 Mar; 20(10):1235-45. PubMed ID: 11313868
[TBL] [Abstract][Full Text] [Related]
31. Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells.
Yang HK; Kang SH; Kim YS; Won K; Bang YJ; Kim SJ
Oncogene; 1999 Apr; 18(13):2213-9. PubMed ID: 10327067
[TBL] [Abstract][Full Text] [Related]
32. Toward an optimum system for intervertebral disc organ culture: TGF-beta 3 enhances nucleus pulposus and anulus fibrosus survival and function through modulation of TGF-beta-R expression and ERK signaling.
Risbud MV; Di Martino A; Guttapalli A; Seghatoleslami R; Denaro V; Vaccaro AR; Albert TJ; Shapiro IM
Spine (Phila Pa 1976); 2006 Apr; 31(8):884-90. PubMed ID: 16622376
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic carcinoma cell lines with SMAD4 inactivation show distinct expression responses to TGFB1.
Jonson T; Heidenblad M; Håkansson P; Gorunova L; Johansson B; Fioretos T; Höglund M
Genes Chromosomes Cancer; 2003 Apr; 36(4):340-52. PubMed ID: 12619158
[TBL] [Abstract][Full Text] [Related]
34. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
35. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
36. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis.
Jonckheere N; Perrais M; Mariette C; Batra SK; Aubert JP; Pigny P; Van Seuningen I
Oncogene; 2004 Jul; 23(34):5729-38. PubMed ID: 15184872
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer.
Kang SH; Bang YJ; Im YH; Yang HK; Lee DA; Lee HY; Lee HS; Kim NK; Kim SJ
Oncogene; 1999 Dec; 18(51):7280-6. PubMed ID: 10602482
[TBL] [Abstract][Full Text] [Related]
38. Effect of transforming growth factor-beta1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines.
Fukuda M; Ikuta K; Yanagihara K; Tajima M; Kuratsune H; Kurata T; Sairenji T
Virology; 2001 Sep; 288(1):109-18. PubMed ID: 11543663
[TBL] [Abstract][Full Text] [Related]
39. Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines.
Zeinoun Z; Teugels E; De Bleser PJ; Neyns B; Geerts A; De Greve J
Anticancer Res; 1999; 19(1A):413-20. PubMed ID: 10226576
[TBL] [Abstract][Full Text] [Related]
40. Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells.
Jiang W; Tillekeratne MP; Brattain MG; Banerji SS
Biochemistry; 1997 Dec; 36(48):14786-93. PubMed ID: 9402753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
